Assembly Biosciences, Inc. News Releases https://investor.assemblybio.com/ Assembly Biosciences, Inc. News Releases en Development Veteran Steven J. Knox Joins Assembly Biosciences as Senior Vice President, Clinical Development https://investor.assemblybio.com/news-releases/news-release-details/development-veteran-steven-j-knox-joins-assembly-biosciences SAN FRANCISCO , April 22, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Steven J. Mon, 22 Apr 2019 16:51:00 -0400 Assembly Biosciences, Inc. News Releases 9846 Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019 https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-presents-interim-data-two-phase-2a-studies - Favorable safety and tolerability profile - Superior antiviral activity with ABI-H0731 in combination with nucleos(t)ide therapies - Selected for inclusion in “Best of ILC” presentation - Company to host conference call Monday, April 15, 2019 at 8am EDT SAN FRANCISCO , April 13, 2019 (GLOBE Sat, 13 Apr 2019 12:00:00 -0400 Assembly Biosciences, Inc. News Releases 9831 Assembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019 https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-presents-data-highlighting-next-generation Phase 1a study of ABI-H2158 demonstrated safety, tolerability and achievement of target liver concentrations ABI-H3733 demonstrated enhanced potency in preclinical studies HBV cccDNA shown to have a limited half-life, suggesting potential for curative treatment regimen Interim data from Phase 2a Thu, 11 Apr 2019 07:05:00 -0400 Assembly Biosciences, Inc. News Releases 9821 Assembly Biosciences Announces Multiple Abstracts Highlighting HBV Core Inhibitor Portfolio Accepted for Oral and Poster Presentations at EASL 2019 https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-announces-multiple-abstracts-highlighting SAN FRANCISCO , March 27, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the acceptance of oral and poster Wed, 27 Mar 2019 07:05:00 -0400 Assembly Biosciences, Inc. News Releases 9751 Assembly Biosciences to Participate in the Jefferies 2019 HBV Summit https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-participate-jefferies-2019-hbv-summit SAN FRANCISCO , March 13, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that Derek Small , Assembly’s Wed, 13 Mar 2019 07:05:00 -0400 Assembly Biosciences, Inc. News Releases 9746 Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-reports-fourth-quarter-and-year-end-2018 SAN FRANCISCO , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today reported financial results for the fourth Thu, 28 Feb 2019 17:00:00 -0500 Assembly Biosciences, Inc. News Releases 9726 Assembly Biosciences Announces Completion of Enrollment in Two Phase 2a Studies with ABI-H0731 for Chronic Hepatitis B Virus https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-announces-completion-enrollment-two-phase Interim results anticipated in Q2 of 2019 SAN FRANCISCO , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today Mon, 07 Jan 2019 07:00:00 -0500 Assembly Biosciences, Inc. News Releases 9686 Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-presents-final-results-phase-1b-study-abi First Presentation of HBV RNA Reduction Data, a Distinguishing Feature of Core Inhibitors SAN FRANCISCO , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and Mon, 12 Nov 2018 07:05:00 -0500 Assembly Biosciences, Inc. News Releases 9651 Assembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-announces-third-quarter-2018-financial ABI-H0731 Phase 2a Clinical Trials Actively Enrolling Patients; Data Continues to be Anticipated in 1H 2019 ABI-H2158 Phase 1a Study Initiated ABI-H3733 Nominated as Third Core Inhibitor Candidate SAN FRANCISCO , Nov. 08, 2018 (GLOBE NEWSWIRE) --   Assembly Biosciences, Inc. Thu, 08 Nov 2018 07:00:00 -0500 Assembly Biosciences, Inc. News Releases 9636 Assembly Biosciences Announces November Conference Participation https://investor.assemblybio.com/news-releases/news-release-details/assembly-biosciences-announces-november-conference-participation SAN FRANCISCO , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced participation at various upcoming Wed, 31 Oct 2018 07:00:00 -0400 Assembly Biosciences, Inc. News Releases 9621